Biotyscience Inc
E-mail biotyscience@gmail.com
info@biotyscience.com
Tel 400-669-8850
Cat No | BIOP2292 |
Conjugate | |
Type | 免疫检查点 |
Source | HEK293 |
Tag | His |
Size | 10 ug |
Application | Immunogen |
Format | Lyophilized |
Concentration | Please refer to the vial lable for the specific concentration. |
Buffer | Supplied in PBS,pH 7.4. |
Species | Rat |
Storage | Store at –20 degree. Avoid repeated freeze/thaw cycles. |
Synonyms | B7-H;B7H1;B7-H1;B7H1PDCD1L1;CD274 antigenMGC142294;CD274 molecule;CD274;PDCD1L1;PDCD1LG1;PDL1;PD-L1;PD-L1B7 homolog 1;PDL1PDCD1 ligand 1;programmed celldeath 1 ligand 1;Programmed death ligand 1 |
Purification | > 95% by SDS-PAGE. |
MolecularWeight | |
Description | aa 18-238 |
Background | PD-L1, also known as B7-H1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7family of immune regulatory molecules. PD-L1 is expressed on inflammatory-activated immune cells includingmacrophages, T cells, and B cells, keratinocytes, enothelial and intestinal epithelial cells, as well as a variety ofcarcinomas and melanoma. PD-L1 binds to T cell B7-1/CD80 and PD-1. It suppresses T cell activation andproliferation and induces the apoptosis of activated T cells. It plays a role in the development of immunetolerance by promoting T cell anergy and enhancing regulatory T cell development. PD-L1 favors thedevelopment of anti-inflammatory IL-10 and IL-22 producing dendritic cells and inhibits the development ofTh17 cells. In cancer, PD-L1 provides resistance to T cell mediated lysis, enhances EMT, and enhances thetumorigenic function of Th22 cells. |